Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPMY Astellas Pharma	$9.51 +1.1%	$9.60	$8.37 ▼ $13.14	N/A	0.23	122,390 shs	400,348 shs
REGN Regeneron Pharmaceuticals	$567.74 +1.4%	$545.98	$476.49 ▼ $1,211.20	$60.43B	0.33	915,680 shs	844,505 shs
SSDOY Shiseido	$17.88 +3.2%	$16.86	$15.32 ▼ $32.17	$6.92B	0.37	35,200 shs	11,083 shs
TAK Takeda Pharmaceutical	$14.67 -1.1%	$14.85	$12.80 ▼ $15.53	$47.22B	0.23	2.00 million shs	3.17 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPMY Astellas Pharma	-0.53%	-1.98%	-3.54%	+6.45%	-6.83%
REGN Regeneron Pharmaceuticals	+1.30%	+2.71%	+6.92%	+1.01%	-47.74%
SSDOY Shiseido	-5.36%	-10.21%	-0.23%	-0.35%	-38.56%
TAK Takeda Pharmaceutical	-2.08%	-4.66%	-2.82%	+6.65%	+11.89%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALPMY Astellas Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	4.9369 of 5 stars	4.4	5.0	1.7	2.3	2.6	1.7	1.9
SSDOY Shiseido	2.1775 of 5 stars	0.0	5.0	0.8	0.0	2.0	0.0	1.9
TAK Takeda Pharmaceutical	1.4908 of 5 stars	0.0	3.0	2.5	0.0	3.2	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPMY Astellas Pharma	0.00	N/A	N/A	N/A
REGN Regeneron Pharmaceuticals	2.80	Moderate Buy	$814.57	43.48% Upside
SSDOY Shiseido	0.00	N/A	N/A	N/A
TAK Takeda Pharmaceutical	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest REGN, ALPMY, TAK, and SSDOY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$560.00 ➝ $584.00
7/10/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$755.00 ➝ $754.00
6/30/2025	REGN Regeneron Pharmaceuticals	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/9/2025	REGN Regeneron Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$950.00 ➝ $800.00
6/5/2025	REGN Regeneron Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$633.00 ➝ $560.00
6/2/2025	REGN Regeneron Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$700.00 ➝ $650.00
6/2/2025	REGN Regeneron Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$800.00 ➝ $600.00
6/2/2025	REGN Regeneron Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$958.00 ➝ $755.00
5/30/2025	REGN Regeneron Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/30/2025	REGN Regeneron Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold	$662.00

(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPMY Astellas Pharma	$12.56B	N/A	$1.82 per share	5.23	$5.52 per share	N/A
REGN Regeneron Pharmaceuticals	$14.20B	4.32	$46.35 per share	12.25	$268.50 per share	2.11
SSDOY Shiseido	$6.55B	1.09	$1.06 per share	16.84	$10.44 per share	1.71
TAK Takeda Pharmaceutical	$30.09B	1.55	$3.14 per share	4.67	$14.39 per share	1.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPMY Astellas Pharma	$334.93M	$0.17	55.94	13.99	N/A	2.65%	16.55%	7.35%	7/29/2025 (Estimated)
REGN Regeneron Pharmaceuticals	$4.41B	$39.28	14.45	14.93	2.08	31.94%	15.27%	11.93%	8/1/2025 (Estimated)
SSDOY Shiseido	-$68.94M	-$0.07	0.00	21.54	N/A	-0.40%	-0.61%	-0.30%	8/6/2025 (Estimated)
TAK Takeda Pharmaceutical	$712.33M	$0.22	9.39	8.89	N/A	2.36%	10.64%	5.14%	7/30/2025 (Estimated)

Latest REGN, ALPMY, TAK, and SSDOY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/1/2025	Q2 2025	REGN Regeneron Pharmaceuticals	$8.53	N/A	N/A	N/A	$3.30 billion	N/A
7/30/2025	Q1 2026	TAK Takeda Pharmaceutical	$0.47	N/A	N/A	N/A	$7.96 billion	N/A
5/12/2025	Q1 2025	SSDOY Shiseido	$0.0569	$0.06	+$0.0031	$0.06	$1.72 billion	$1.54 billion
5/8/2025	Q4 2025	TAK Takeda Pharmaceutical	$0.24	$0.16	-$0.08	-$0.21	$8.02 billion	$7.34 billion
4/29/2025	Q1 2025	REGN Regeneron Pharmaceuticals	$8.83	$8.22	-$0.61	$7.27	$3.40 billion	$3.03 billion
4/25/2025	Q4 2025	ALPMY Astellas Pharma	$0.1474	$0.27	+$0.1226	$0.27	$3.02 billion	$3.22 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPMY Astellas Pharma	$0.35	3.68%	N/A	205.88%	N/A
REGN Regeneron Pharmaceuticals	$3.52	0.62%	N/A	8.96%	N/A
SSDOY Shiseido	$0.08	0.45%	N/A	N/A	N/A
TAK Takeda Pharmaceutical	$0.55	3.75%	N/A	250.00%	N/A

Latest REGN, ALPMY, TAK, and SSDOY Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/20/2025	REGN Regeneron Pharmaceuticals	quarterly	$0.88	0.6%	5/20/2025	5/20/2025	6/6/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPMY Astellas Pharma	0.37	1.13	0.85
REGN Regeneron Pharmaceuticals	0.09	4.93	4.03
SSDOY Shiseido	0.36	1.20	0.79
TAK Takeda Pharmaceutical	0.57	1.01	0.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPMY Astellas Pharma	N/A
REGN Regeneron Pharmaceuticals	83.31%
SSDOY Shiseido	0.02%
TAK Takeda Pharmaceutical	9.17%

Insider Ownership

Company	Insider Ownership
ALPMY Astellas Pharma	N/A
REGN Regeneron Pharmaceuticals	7.02%
SSDOY Shiseido	N/A
TAK Takeda Pharmaceutical	0.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPMY Astellas Pharma	14,754	N/A	N/A	Not Optionable
REGN Regeneron Pharmaceuticals	15,106	107.96 million	100.39 million	Optionable
SSDOY Shiseido	27,908	399.66 million	N/A	Not Optionable
TAK Takeda Pharmaceutical	47,455	3.18 billion	3.18 billion	Optionable

REGN, ALPMY, TAK, and SSDOY Headlines

Recent News About These Companies

Takeda: Positives And Negatives Offset Each Other

July 11 at 8:04 AM | seekingalpha.com

Vontobel Holding Ltd. Acquires New Shares in Takeda Pharmaceutical Co. (NYSE:TAK)

July 9 at 3:47 AM | marketbeat.com

Crossmark Global Holdings Inc. Purchases 186,349 Shares of Takeda Pharmaceutical Co. (NYSE:TAK)

July 8 at 6:42 AM | marketbeat.com

Callan Capital LLC Invests $735,000 in Takeda Pharmaceutical Co. (NYSE:TAK)

July 8 at 6:10 AM | marketbeat.com

Takeda Completes Treasury Share Disposal with Minor Adjustments

July 8 at 4:06 AM | tipranks.com

Lupin gets USFDA approval for post-eye surgery drug

July 2, 2025 | indiainfoline.comI

Takeda Pharmaceutical Co. (NYSE:TAK) Stock Position Raised by Sequoia Financial Advisors LLC

July 1, 2025 | marketbeat.com

FDA Approves Takeda’s Gammagard Liquid ERC

June 30, 2025 | contractpharma.comC

Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High - What's Next?

June 30, 2025 | marketbeat.com

Sclerosing Mesenteritis: What GIs Need to Know About This Rare Disease

June 28, 2025 | medscape.comM

Herbosa cites Dengvaxia lesson as PH mulls approval of Qdenga vaccine

June 28, 2025 | gmanetwork.comG

Sun Pharma appoints Richard Ascroft as North American CEO

June 27, 2025 | emjreviews.comE

Lupin gets U.S. FDA nod for generic of Takeda’s constipation drug

June 25, 2025 | thehindu.com

Sun Pharma Announces Appointment of Richard Ascroft as CEO North America

June 25, 2025 | finance.yahoo.com

ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today?

June 25, 2025 | zacks.com

Lupin gets approval from U.S FDA for Prucalopride Tablets

June 25, 2025 | uniindia.comU

Lupin receives USFDA approval for Prucalopride Tablets

June 25, 2025 | business-standard.comB

USFDA okays Lupin Prucalopride Tablets for chronic idiopathic constipation

June 25, 2025 | medicaldialogues.inM

Lupin receives US FDA approval for drug used to treat bowel disorder

June 25, 2025 | cnbctv18.comC

Takeda Announces New Assignments of Directors

June 25, 2025 | businesswire.com

Takeda Pharmaceutical Co Ltd ADR Key Metrics - Morningstar

June 24, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Applied Digital: Now the High-Stakes Race to Build Begins
By Jeffrey Neal Johnson | June 17, 2025
View Applied Digital: Now the High-Stakes Race to Build Begins
Lululemon, UNH, Enphase: Bad News, Good Opportunity?
By Thomas Hughes | June 17, 2025
View Lululemon, UNH, Enphase: Bad News, Good Opportunity?
The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
By Leo Miller | July 2, 2025
View The Ultimate Trump Bump: These Gov't Backed Stocks Are Exploding
Retail Sales Signal Upside for These 3 Consumer Stocks
By Gabriel Osorio-Mazilli | June 22, 2025
View Retail Sales Signal Upside for These 3 Consumer Stocks
Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off
By Chris Markoch | July 6, 2025
View Forget the Weak Dollar—These 3 Travel Stocks Are Still Taking Off

REGN, ALPMY, TAK, and SSDOY Company Descriptions

Astellas Pharma OTCMKTS:ALPMY

$9.51 +0.10 (+1.06%)

As of 03:59 PM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Regeneron Pharmaceuticals NASDAQ:REGN

$567.74 +7.98 (+1.43%)

Closing price 04:00 PM Eastern

Extended Trading

$567.00 -0.74 (-0.13%)

As of 07:59 PM Eastern

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Shiseido OTCMKTS:SSDOY

$17.88 +0.56 (+3.23%)

As of 03:58 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical NYSE:TAK

$14.67 -0.17 (-1.15%)

Closing price 03:59 PM Eastern

Extended Trading

$14.68 +0.02 (+0.10%)

As of 07:42 PM Eastern

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time